TB drug dosing under the microscope: could this lead to shorter, safer treatment?
NCT ID NCT02563327
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 3 study measured how high doses of the tuberculosis drugs rifapentine and moxifloxacin move through the body in 53 adults with TB. Participants gave multiple blood samples to track drug levels. The goal was to understand the best doses to kill TB bacteria while avoiding side effects. This research may help refine future TB treatment regimens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
What this could lead to
If successful, this study could help doctors choose the best doses of these TB drugs to cure patients faster and with fewer side effects.
What could go wrong
This is a small, intensive sampling study (53 participants) that looks at drug levels in the body, not a direct test of a new cure. Results may not apply to all TB patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Joint Clinical Research Centre/ Makerere Univ Med Sch
Kampala, Uganda
-
National TB Program
Hanoi, Vietnam
-
University of Texas Health Science Center at
San Antonio, Texas, United States